 OKYO Pharma Ltd LSE:OKYO, NASDAQ:OKYO said its dry eye disease treatment has received its investigational new drug IND application from the US Food and Drug Administration FDA to initiate a phase 2 study. First-in-human clinical studies of OK-101 are expected to open for enrolment in the first quarter of 2023, the biopharmaceutical company said. 